Julie Barta is a Respiratory physician affiliated with Thomas Jefferson University. OpenAlex indexes 126 publications with 2,324 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
834 Walnut St
Suite 650
Philadelphia, PA 191075109
Telephone
215-955-5161Registry record last updated 17 Aug 2015.
Clinical trials
- Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Actelion Pharmaceuticals US, Inc.Program year20241 payment
- Actelion Pharmaceuticals US, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
83.6%Corticosteroid34.5%Trelegy Ellipta50%Fluticasone Propionate27%Breo Ellipta8%Budesonide-Formoterol Fumarate6%Symbicort5%Arnuity Ellipta4%Part D<11 patientsbeta2-Adrenergic Agonist31.3%Albuterol Sulfate Hfa82%Ventolin Hfa18%Part D≥81 patients+ 4 more classes in this area
Metabolism & gastrointestinal
9.9%Proton pump inhibitor5.6%Omeprazole80%Pantoprazole Sodium20%Part D<11 patientsH2 blocker2.6%Famotidine100%Part D≥11 patients+ 1 more class in this area
Nervous system
4.1%Cholinergic Receptor Agonist4.1%Varenicline Tartrate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Geospatial Analysis of the Lung Cancer Burden in Philadelphia, Using Pennsylvania Cancer Registry Data from 2008–2017
International Journal of Environmental Research and Public Health
2025 - Using an Integrated, Digital Framework to Standardize and Expand a Multisite Lung Cancer Screening Program
JCO Clinical Cancer Informatics
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Carol Shields, MD
Thomas Jefferson University
Joseph Bavaria, MD
Thomas Jefferson University
Michele Meltzer, MD
Thomas Jefferson University
Marinos Dalakas, MD
Thomas Jefferson University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”